Autoinjectors Market

Autoinjectors Market

Growth Factors of Autoinjectors Market

The autoinjectors market size was valued at USD 518.46 billion in 2023, and the market is now projected to grow from USD 542.21 billion in 2024 to USD 886.80 billion by 2032, exhibiting a CAGR of 6.3% during the forecast period of 2023-2030.

The COVID-19 pandemic posed significant challenges on the autoinjectors market growth. Due to lack of industrial operations and a halt in commercial campaigns, implementation of government policies, investments in projects and other initiatives due to covid pandemic., which lead a decline in the autoinjectors market expansion. Lockdown enacted in numerous nations have hindered the manufacturing and caused transportation delays. In addition, worldwide restrictions have caused a halt in economic activities. Despite the challenges of covid pandemic, the battery plate sector has proven to be robust. Although the construction of electric vehicle has been delayed due to shortage of man power and procurement concerns of raw material.

Technological developments in device platforms to present profitable will promote autoinjectors market growth prospects during projected period. The increasing prevalence of chronic illnesses like diabetes and rheumatoid arthritis is driving up demand for autoinjectors worldwide. In order to facilitate quicker development and lower device costs, a number of market participants are reorienting their attention toward the development of platform device technologies as a result of the high incidence. Furthermore, market expansion will be fueled by major players' increased focus on enabling high-volume delivery of a variety of biologics and biosimilars for patients in their homes.

Patients' widespread adoption of disposable autoinjectors to accelerate market growth during projected period. Injectable systems have been used by medical practitioners as practical medication delivery tools for administering subcutaneous injections to patients. However, patients' desire for conventional injectable devices was constrained by drawbacks such needle stick injuries, repeated low-dose injections, and high hospital visit expenses.

Comprehensive Analysis of Autoinjectors Market

The autoinjectors market and healthcare industry is rising at an exponential rate due to its market segmentation. This market expansion effectively provides a detailed regional assessment considering the dominant supply and demand forces that impact the pharmacy benefit management industry. These segmentations are methodically segregated by types, by route of application, by route of administration and by end users. The types segmentations include, Disposable, and Reusable, and by Application segmentations include Autoimmune Disorders, Diabetes, Emergency Care, and Others wile by Route of Administration segmentations include Intramuscular and Subcutaneous. However, the Distribution Channel segmentations include Hospitals Pharmacies, Retail Pharmacies, and Online Pharmacies.

The North America region lead the autoinjectors market by benefitting a market size of USD 65.81 billion in 2023 due to the major players' increased R&D and the development of new technology in self-injector devices to enable in-patient treatment, as well as the growing emphasis and recommendation of autoinjector prescriptions against anaphylactic episodes by healthcare professionals.

The top players in the market play a crucial role in the healthcare industry assuring industrial prospectus growth and setting market standards. These players include, Viatris Inc. (U.S.), Teva Pharmaceuticals, Inc. (Netherlands), Ypsomed AG (Switzerland), Recipharm AB (Sweden), Becton Dickinson and Company (U.S.), Halozyme, Inc. (U.S.), AstraZeneca (U.K.), Bristol-Myers Squibb (U.S.), Phillips-Medisize (U.S.), SHL Medical AG (Switzerland), Xeris Pharmaceuticals, Inc. (U.S.) these market players provide a level-playing competitive landscape.

In April 2022, Halozyme Therapeutics, Inc. entered a final agreement to buy Antares Pharma, Inc. A market leader in the autoinjector platform business for specialized goods and medication delivery was created through the purchase.

Segmentation Table

ATTRIBUTE DETAILS

Study Period 2019-2032

Base Year 2023

Estimated Year 2024

Forecast Period 2024-2032

Historical Period 2019-2022

Growth Rate CAGR of 12.3% over 2024 to 2032

Unit Value (USD billion)

Growth Rate CAGR of 12.3% from 2024-2032

Segmentation By Type

• Disposable
• Reusable

By Application

• Autoimmune Disorders
• Diabetes
• Emergency Care
• Others

By Route of Administration

• Intramuscular
• Subcutaneous

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Geography

• North America (By Type, By Application, By Distribution Channel, and By Country)
• U.S. (By Type)
• Canada (By Type)
• Europe (By Type, By Diabetes Type, By Distribution Channel, and By Country/Sub-region)
• U.K. (By Type)
• Germany (By Type)
• France (By Type)
• Italy (By Type)
• Spain (By Type)
• Rest of Europe (By Type)
• Asia Pacific (By Type, By Application, By Distribution Channel, and By Country/Sub-region)
• China (By Type)
• Japan (By Type)
• India (By Type)
• Australia (By Type)
• Southeast Asia (By Type)
• Rest of Asia Pacific (By Type)
• Latin America (By Type, By Application, By Distribution Channel, and By Country/Sub-region)
• Brazil (By Type)
• Mexico (By Type)
• Rest of Latin America (By Type)
• Middle East & Africa (By Type, By Application, By Distribution Channel, and By Country/Sub-region)
• GCC (By Type)
• South Africa (By Type)
• Rest of Middle East & Africa (By Type)

Please Note: It will take 5-6 business days to complete the report upon order confirmation.